BioTime, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their pharmaceutical products and clinical research.
As per AST-OPC1 product pipeline, “AST-OPC1 is now in Phase I/IIa clinical trial in patients with complete cervical spinal cord injury, and is funded in part through a $14.5 million grant from the California Institute for Regenerative Medicine (CIRM). The goal of this clinical trial is to test the safety of the product in the cervical region of the spine and to escalate the dose in human patients to levels comparable to those already demonstrated as effective in an animal model of the disorder.” Read the Full article.
BioTime, Inc. engages in biotechnology business. It focuses on research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA. [Source: MarketWatch]